The African Society of Hypertension (AfSoH) Initiative is an international organization initiative with the objective to create the African Society of Hypertension with a main goal of providing a stable and organized African platform for scientific exchange in arterial hypertension. The AfSoH Initiative was created in 2010 by the consortium of health professionals and researchers active in field of arterial hypertension on African continent led by Marc Twagirumukiza. The official membership is obtained after registration.
Meetings
editThe society organizes bi-annual meetings in different African cities[1] as well as summer schools.[2]
Research activities
editThe AfSoH Initiative areas of research activities are illustrated by the different task forces:
- Task force 1: Mapping the arterial hypertension prevalence on the continent and make predictions for near future.
- Task force 2: Mapping the prevalence of arterial hypertension risk factors and related CV risk factors
- II-a Traditionally risk factors : which covers the risk factors like the sedentary lifestyle,[3] smoking, and stress. This list includes also other factors like the aging,[4] renin related patterns,[5] or sympathetic nervous system related issues.[6]
- II-b: Arterial stiffness and other emerging risk factors
- II-c: Genetic factors: which covers all potential genetic mutations,[7] and family history of hypertension related research.[8]
- II-d: Nutritional and metabolic risk factors : which covers all components of syndrome X (or the metabolic syndrome), like the Insulin resistance,[5][9] obesity,[10][11] salt (sodium) sensitivity,[12] alcohol intake,[13] and vitamin D deficiency.[14][15] as well as all potassium deficiency related risk factors (hypokalemia),[3]
- II-e: The new risk factors and experimental discovery : which covers the new or still debatable or under discovery factors like low birth weight,[16] and others.
- Task force 3: Prevention and intervention research in primary care which covers all health systems, policy, and primary care research.
- Task force 4: Treatment strategies for hypertension on African continent (guidelines, clinical trials - Cost effectiveness- Access to medicines-EBM, etc.)
- Task force 5: Community advocacy, education and communication
References
edit- ^ African Society of Hypertension(AfSoH) Initiative
- ^ Summer School of Hypertension
- ^ a b Kyrou I, Chrousos GP, Tsigos C (November 2006). "Stress, visceral obesity, and metabolic complications". Annals of the New York Academy of Sciences. 1083: 77–110. doi:10.1196/annals.1367.008. PMID 17148735.
- ^ Kosugi T, Nakagawa T, Kamath D, Johnson RJ (February 2009). "Uric acid and hypertension: an age-related relationship?". J Hum Hypertens. 23 (2): 75–6. doi:10.1038/jhh.2008.110. PMID 18754017.
- ^ a b Segura J, Ruilope LM (October 2007). "Obesity, essential hypertension and renin-angiotensin system". Public Health Nutrition. 10 (10A): 1151–5. doi:10.1017/S136898000700064X. PMID 17903324.
- ^ Rahmouni K, Correia ML, Haynes WG, Mark AL (January 2005). "Obesity-associated hypertension: new insights into mechanisms". Hypertension. 45 (1): 9–14. doi:10.1161/01.HYP.0000151325.83008.b4. PMID 15583075.
- ^ Dickson ME, Sigmund CD (July 2006). "Genetic basis of hypertension: revisiting angiotensinogen". Hypertension. 48 (1): 14–20. doi:10.1161/01.HYP.0000227932.13687.60. PMID 16754793.
- ^ Luma GB, Spiotta RT (May 2006). "Hypertension in children and adolescents". Am Fam Physician. 73 (9): 1558–68. PMID 16719248.
- ^ Sorof J, Daniels S (October 2002). "Obesity hypertension in children: a problem of epidemic proportions". Hypertension. 40 (4): 441–7. doi:10.1161/01.HYP.0000032940.33466.12. PMID 12364344. Archived from the original on 2012-12-05. Retrieved 2009-06-03.
- ^ Wofford MR, Hall JE (2004). "Pathophysiology and treatment of obesity hypertension". Current Pharmaceutical Design. 10 (29): 3621–37. doi:10.2174/1381612043382855. PMID 15579059. Archived from the original on 2009-06-15. Retrieved 2019-09-18.
{{cite journal}}: CS1 maint: unfit URL (link) - ^ Haslam DW, James WP (2005). "Obesity". Lancet. 366 (9492): 1197–209. doi:10.1016/S0140-6736(05)67483-1. PMID 16198769.
- ^ Lackland DT, Egan BM (August 2007). "Dietary salt restriction and blood pressure in clinical trials". Curr. Hypertens. Rep. 9 (4): 314–9. doi:10.1007/s11906-007-0057-8. PMID 17686383.
- ^ Djoussé L, Mukamal KJ (June 2009). "Alcohol consumption and risk of hypertension: does the type of beverage or drinking pattern matter?". Revista Española De Cardiología. 62 (6): 603–5. doi:10.1016/S1885-5857(09)72223-6. PMID 19480755. Archived from the original on 2013-04-15.
- ^ Tuohimaa P (March 2009). "Vitamin D and aging". The Journal of Steroid Biochemistry and Molecular Biology. 114 (1–2): 78–84. doi:10.1016/j.jsbmb.2008.12.020. PMID 19444937.
- ^ Lee JH, O'Keefe JH, Bell D, Hensrud DD, Holick MF (2008). "Vitamin D deficiency an important, common, and easily treatable cardiovascular risk factor?". J. Am. Coll. Cardiol. 52 (24): 1949–56. doi:10.1016/j.jacc.2008.08.050. PMID 19055985.
- ^ Uchiyama M (August 2008). "[Mild hypertension in children]". Nippon Rinsho (in Japanese). 66 (8): 1477–80. PMID 18700545.